| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
(Biotech Stocks Hitting 52-week Highs Aug. 3)
(Biotech Stocks Hitting 52-week Lows July 30)
Voyager Therapeutics Inc (NASDAQ:VYGR) announced the termination of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie Inc (NYSE:ABBV). Voyager said it now retains full rights to the vectorization technology and certain novel vectorized antibodies developed as part of the collaborations.
The research collaborations — announced in 2018 and 2019, respectively — called for Voyager to receive upfront payments for conducting research and preclinical studies.
Voyager said it does not expect its cash runway guidance to be impacted due to the termination.
Voyager shares were down 10.41% at $10.15 in Tuesday's premarket session.
TIZIANA LF SCIE/S ADR (NASDAQ:TLSA) said it has signed agreements with four CROs to expedite clinical development of TZLS-501, a novel fully human anti-interleukin-6 receptor monoclonal antibody for the treatment of COVID-19 patients. Tiziana expects to commence the clinical study in the first quarter of 2021.
In premarket trading Tuesday, Tiziana shares were rallying 9.49% to $6.
DBV TECHNOLOGIE/S ADR (NASDAQ:DBVT) said the FDA has issued a Complete Response Letter regarding its BLA for investigational Viaskin Peanut, a non-invasive, once-daily epicutaneous patch to treat peanut allergies in children ages 4-11.
In the letter, the FDA identified concerns regarding the impact of patch-site adhesion on efficacy and indicated the need for patch modifications and subsequently a new human factor study, the company said.
Supplementary clinical data will need to be generated to support the modified patch, according to DBV, citing the FDA. In addition, the FDA requested additional Chemistry, Manufacturing and Controls data.
The stock was slumping 34.39% to $2.69 in premarket trading Tuesday.
See also: The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
Novartis AG (NYSE:NVS) announced positive results from the Phase 2 ELARA trial of Kymriah in patients with relapsed or refractory follicular lymphoma.
At the interim analysis, the global study met its primary endpoint of complete response rate, as assessed by independent review committee, Novartis said. No new Kymriah safety signals were observed, according to Novartis.
Alterity Therapeutics Ltd (NASDAQ:ATHE) said new data from an experiment testing its lead candidate ATH434 in an animal model of Multiple System Atrophy independently confirmed and extended previous findings demonstrating that ATH434 reduces α-synuclein pathology, preserves neurons and improves motor performance.
The stock was skyrocketing 211.11% to $4.20 in premarket trading Tuesday.
Karuna Therapeutics Inc (NASDAQ:KRTX) said topline results of an exploratory Phase 1b trial did not provide conclusive evidence of an analgesic benefit of KarXT on experimentally induced pain in healthy volunteers.
The company said it will not proceed with the evaluation of KarXT for the treatment of pain.
DURECT Corporation's (NASDAQ:DRRX) second-quarter revenues increased from $4 million to $14.3 million. The company reversed from a loss of 4 cents per share to a profit of 7 cents per share. Analysts, on average, estimated EPS of 1 cent.
In premarket trading, the stock jumped 7.46% to $2.52.
Pacific Biosciences of California Inc (NASDAQ:PACB) said its second-quarter revenues declined from $24.6 million in 2019 to $17.1 million in 2020. The loss per share narrowed from 16 cents to 15 cents, while the consensus estimate had called for 18 cents per share.
The stock fell 5.37% to $3.70 in after-hours trading.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) reported second-quarter revenues that increased from $183.5 million in 2019 to $302.4 million in 2020 on strong Ingrezza sales. Non-GAAP EPS increased from 71 cents to $1.42.
The stock was up 3.25% to $127.01 premarket.
Veracyte Inc (NASDAQ:VCYT) said it has commenced an underwritten public offering of 6 million shares of its common stock. All of the shares are being offered by the company.
Veracyte intends to use the net proceeds from the offering for working capital and other general corporate purposes, and also for acquiring or investing in complementary businesses, technologies or other assets.
The stock was down 3.09% premarket at $34.21.
Achieve Life Sciences, Inc. (NASDAQ:ACHV) announced a proposed underwritten public offering in which it intends to offer shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock.
The stock was down 8.28% premarket at $10.75.
BioSig Technologies Inc (NASDAQ:BSGM) CEO Kenneth Londoner will present at the Proactive Investors One2One Virtual Event with an update on a Phase 2 clinical study of merimepodib in combination with remdesivir in adult patients with advanced COVID-19.
Related Link: Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
Posted In: ABBV ABMD ACHV ACOR AKCA ALXO AMRN ANNX AQST ATHE ATOS AVNS AXNX BMRN BSGM CDNA CERS CODX CORT CRIS
